Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

NCT00276159 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Drug was not available.

Conditions

Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Non-Hodgkin's Lymphoma
Hodgkin's Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia

Interventions

DRUG: 852A

Sponsor

Masonic Cancer Center, University of Minnesota

Collaborators

[object Object]